Completed PHASE2 INTERVENTIONAL 2-arm NCT00528242

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease.

Sponsor: Response Pharmaceuticals

Conditions Raynaud's Disease

Interventions Placebo SLx-2101

Updated 8 times since 2017 Last updated: Nov 14, 2023 Started: Jun 30, 2007 Primary completion: Mar 31, 2008 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00528242, this PHASE2 trial focuses on Raynaud's Disease and remains completed. Sponsored by Response Pharmaceuticals, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2023 — Jul 2024 [monthly]

Completed PHASE2
Apr 2022 — Dec 2023 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Response Pharmaceuticals

Data source: Response Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Homburg, Germany